title: Short term prophylaxis against heterotopic bone after cementless hip replacement.
abstract: The aim of the current study was to reveal whether 7 days of indomethacin treatment sufficiently prevents heterotopic ossification after cementless total hip arthroplasty. One group received indomethacin for 14 days (n = 102), and the second for 7 days (n = 99) after cementless total hip arthroplasty. At followup 1 year postoperatively, the average Harris Hip Score was 91 points in the 14-day treatment group and 89 points in the 7-day treatment group. The incidence of heterotopic ossification as outlined by Brooker was similar in both groups. Ninety-six patients in the 14-day treatment group had heterotopic ossification Grades 0 or 1, and 6 patients had Grade II heterotopic ossification; whereas in the 7-day treatment group, 95 patients had Grades 0 or 1 heterotopic ossification and 4 patients had Grade II ossification. None of the patients had Grades III or IV heterotopic ossification. In the 14-day treatment group, headache, dizziness, or gastritic disorders develop in 10 patients, and in the 7-day treatment group, 7 patients had these effects. This study shows that treatment with 100 mg indomethacin daily for 7 days is not significantly different than 14 days of treatment for the prevention of formation of severe heterotopic ossification after cementless hip arthroplasty.
authors.affiliation: Department of Orthopaedics, University of Vienna, Wahringer Gurtel, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Wurnig
authors.forename: V
authors.initials: V
authors.lastname: Auersperg
authors.forename: N
authors.initials: N
authors.lastname: Boehler
authors.forename: M
authors.initials: M
authors.lastname: Steindl
authors.forename: H
authors.initials: H
authors.lastname: Kiss
authors.forename: K
authors.initials: K
authors.lastname: Zweymuller
authors.forename: R
authors.initials: R
authors.lastname: Kotz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006622:Hip Prosthesis / Q000379:methods*; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009999:Ossification, Heterotopic / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011474:Prosthesis Design; D016896:Treatment Outcome
chemical_list: D007213:Indomethacin